Lilly’s Zepbound Resolves Sleep Apnea in 52% of Patients by Mark Eisenberg 22.06.2024 Eli Lilly's Zepbound reduces sleep apnea by up to 52% in trials, showing promise beyond weight loss. FDA approval for ...
Nanox 2023 Earnings Call: ARC System in Action by John Darbie 08.04.2024 Nanox Imaging reports fourth-quarter 2023 earnings with progress in the utilization of ARC systems, scanning patients. CEO suggests varying connection ...
Akero Therapeutics MASH Treatment Trial Data: Stock Up 21% by Mark Eisenberg 04.03.2024 The stock has dropped 29% in the last year, hitting a low of $11.25 on Oct. 27. A study shows ...
TransMedics: 2023 Earnings & Future Insights by Mark Eisenberg 13.02.2024 Medical technology company TransMedics Group, Inc. is set to release its Q4 and full year 2023 financial results, highlighting its ...
Gilead’s $4.3B Bet on CymaBay’s Liver Drug by Mark Eisenberg 12.02.2024 Gilead Sciences plans to acquire CymaBay Therapeutics for $4.3 billion, expanding their liver disease portfolio. The deal is expected to ...
Gilead Acquires CymaBay: Liver Cure Leap? by Mark Eisenberg 12.02.2024 Gilead Sciences acquires CymaBay Therapeutics for $4.3 billion to expand its liver disease portfolio, including access to potential treatment for ...